IL288503A - Preparations of leuprolide acetate and methods of using them for the treatment of breast cancer - Google Patents

Preparations of leuprolide acetate and methods of using them for the treatment of breast cancer

Info

Publication number
IL288503A
IL288503A IL288503A IL28850321A IL288503A IL 288503 A IL288503 A IL 288503A IL 288503 A IL288503 A IL 288503A IL 28850321 A IL28850321 A IL 28850321A IL 288503 A IL288503 A IL 288503A
Authority
IL
Israel
Prior art keywords
methods
same
breast cancer
leuprolide acetate
treat breast
Prior art date
Application number
IL288503A
Other languages
English (en)
Hebrew (he)
Inventor
John Middleton
Avinash Nangia
John Arthur Mclane
Terri L Morton
Original Assignee
Tolmar International Ltd
John Middleton
Avinash Nangia
John Arthur Mclane
Terri L Morton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd, John Middleton, Avinash Nangia, John Arthur Mclane, Terri L Morton filed Critical Tolmar International Ltd
Publication of IL288503A publication Critical patent/IL288503A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL288503A 2019-05-27 2021-11-28 Preparations of leuprolide acetate and methods of using them for the treatment of breast cancer IL288503A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27
PCT/IB2020/054984 WO2020240417A1 (en) 2019-05-27 2020-05-26 Leuprolide acetate compositions and methods of using the same to treat breast cancer

Publications (1)

Publication Number Publication Date
IL288503A true IL288503A (en) 2022-01-01

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288503A IL288503A (en) 2019-05-27 2021-11-28 Preparations of leuprolide acetate and methods of using them for the treatment of breast cancer

Country Status (17)

Country Link
US (2) US12453754B2 (cg-RX-API-DMAC7.html)
EP (1) EP3975990A1 (cg-RX-API-DMAC7.html)
JP (1) JP7664855B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220041782A (cg-RX-API-DMAC7.html)
CN (1) CN114144169A (cg-RX-API-DMAC7.html)
AR (1) AR119021A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020284587B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023904A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141456A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193257A1 (cg-RX-API-DMAC7.html)
IL (1) IL288503A (cg-RX-API-DMAC7.html)
MX (1) MX2021014540A (cg-RX-API-DMAC7.html)
PH (1) PH12021552976A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112888RA (cg-RX-API-DMAC7.html)
TW (1) TWI757753B (cg-RX-API-DMAC7.html)
UY (1) UY38717A (cg-RX-API-DMAC7.html)
WO (1) WO2020240417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112888RA (en) 2019-05-27 2021-12-30 Tolmar International Ltd Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR102742097B1 (ko) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 혼합 주사기 밸브 어셈블리를 위한 시스템 및 방법
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2637569C (en) * 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
EP3202814B1 (en) * 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
SG11202112888RA (en) 2019-05-27 2021-12-30 Tolmar International Ltd Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
KR102742097B1 (ko) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 혼합 주사기 밸브 어셈블리를 위한 시스템 및 방법
AU2022331238A1 (en) 2021-08-19 2024-02-01 Carefusion 303, Inc. Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Also Published As

Publication number Publication date
US20220265760A1 (en) 2022-08-25
AU2020284587B2 (en) 2025-09-18
CN114144169A (zh) 2022-03-04
US20260027176A1 (en) 2026-01-29
AR119021A1 (es) 2021-11-17
KR20220041782A (ko) 2022-04-01
US12453754B2 (en) 2025-10-28
PH12021552976A1 (en) 2022-07-04
UY38717A (es) 2020-11-30
TWI757753B (zh) 2022-03-11
TW202110472A (zh) 2021-03-16
SG11202112888RA (en) 2021-12-30
JP2022535694A (ja) 2022-08-10
MX2021014540A (es) 2022-04-12
BR112021023904A2 (pt) 2022-02-01
JP7664855B2 (ja) 2025-04-18
WO2020240417A1 (en) 2020-12-03
CA3141456A1 (en) 2020-12-03
AU2020284587A1 (en) 2022-01-06
EP3975990A1 (en) 2022-04-06
EA202193257A1 (ru) 2022-03-10

Similar Documents

Publication Publication Date Title
IL268138A (en) Combinations of cabozantinib and atezolizumab for cancer treatment
IL268406A (en) Preparations and methods for treating hemoglobin diseases
IL276808A (en) Preparations and methods for the treatment of cancer
ZA201900960B (en) Methods and compositions for the treatment of cancer
SG11202111672RA (en) Cancer associated antibody compositions and methods of use
SG11202106295WA (en) Compositions and methods for cancer therapy
EP4055040A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER USING LEKTI
IL276203A (en) Compounds and methods for treating cancer
IL280000A (en) Formulations for reducing tumors and methods of using them
ZA201808232B (en) Compositions and methods for the treatment of cancer
PH12021552976A1 (en) Leuprolide acetate compositions and methods of using the same to treat breast cancer
IL277313B (en) Pharmaceutical preparations of sposin c and methods for the treatment of cancer
IL280218A (en) Methods for the treatment of HFPEF using dapagliflozin and compounds containing it
SG11202007005UA (en) Use of crassocephalum rabens extract in the treatment of breast cancer
IL287538A (en) Preparations and methods for the treatment of cancer
IL255169A0 (en) Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer
EP4051260A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
SG11202000724XA (en) Methods and compositions for the treatment of cancer
HK40072135A (en) Leuprolide acetate compositions and methods of using the same to treat breast cancer
IL280262A (en) Compositions and methods for treating cancer
IL287342A (en) Cancer associated antibody compositions and methods of use
HK40075429A (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
GB201903608D0 (en) Compositions and methods relating to the treatment of psoriasis
GB201809005D0 (en) Compositions and methods realting to the treatment of psoriasis
HK40058986A (en) Methods and compositions for treating breast cancer using antisense